Fundamentals scanner

You are paying 31.1 years of current profit for each share. The earnings yield is 3.2%. The tracked Pharma & Healthcare median is 32.2× (n=7), so this trades cheaper than its peers.

The market values the company at 2.6× its accounting net worth. High is normal for asset-light businesses and unusual for banks.

This is the only common multiple that accounts for debt — it is what an actual acquirer would look at, because they would inherit the borrowings.

Pays 0.65% of the current price out each year. Remember that yield rises when price falls — check the dividend is covered by cash flow.

Based on the next-year earnings estimate — 20.4× against 31.1× trailing. A forward P/E well below trailing is pricing in an earnings jump; treat the forecast with caution.

You pay 3.0× annual sales. Useful when earnings are depressed or negative and P/E breaks down — but a high multiple needs high margins to justify it.

Earns ₹8.8 of profit a year for every ₹100 of shareholders' money. Always check how much of this comes from leverage rather than the business.

ROE and ROA are reasonably close, so the returns come largely from the business itself rather than from borrowing.

Keeps ₹4.3 of operating profit from every ₹100 of sales. Compare only against companies in the same industry.

Sustained high net margins are evidence that something is stopping competitors from competing the profits away.

Keeps ₹50.2 of gross profit per ₹100 of sales, before operating costs. A high, stable gross margin is the clearest single sign of pricing power.

A conservative balance sheet that can absorb a downturn without a crisis.

Short-term obligations are comfortably covered by short-term assets.

The current ratio stripped of inventory — a stricter test of whether near-term bills can be met without selling stock. Below 1 means the company is relying on inventory turning to cash.

Against cash of ₹8142.70 Cr. Net debt is what matters, not gross borrowings.

Spends more on capital than it generates from operations. Fine during an expansion phase, dangerous if it persists.

Ask where the growth came from: more volume, higher prices, or an acquisition. They are very different in quality.

Profits are growing slower than sales, meaning margins are compressing. The company may be buying its growth.

EBITDA of ₹5467.20 Cr and operating cash flow of ₹4119.90 Cr.

P/E divided by expected growth. Only as reliable as that growth forecast, which is usually optimistic.

₹38.84 of profit earned per share over the last twelve months. Price divided by this is the trailing P/E.

The accounting net worth behind each share is ₹460.31; price-to-book compares the market price with this.

Pays out 20% of profit as dividends and retains the rest. Above roughly 85% leaves little to reinvest and is hard to sustain through a weak year.

Market cap plus net debt — closer to what an acquirer actually pays. Against a market cap of ₹1,00,475 Cr.